Literature DB >> 12645655

MYCN gain and MYCN amplification in a stage 4S neuroblastoma.

Rosa Noguera1, Adela Cañete, Antonio Pellín, Amparo Ruiz, María Tasso, Samuel Navarro, Victoria Castel, Antonio Llombart-Bosch.   

Abstract

Stage 4S neuroblastoma is a disease associated with spontaneous regression and good survival. We present a patient whose evolution has shown the variety and complexity of this disease in infants. Biologic factors, such as ploidy, MYCN copy number, loss of 1p36, and other chromosomal gains and losses were determined. A complex pattern of genetic abnormalities, such as near-diploidy, MYCN gain (2-4 copies per haploid genome) and imbalance/deletion of 1p36 was seen in the diagnostic sample. An extensive disseminated disease after a latent period of 26 months was associated with a special genetic evolution, such a tetraploidy, MYCN amplification (2:100-500 copies), 1p36 deletion, and gain of 17q. Our results provide evidence that either the primary tumor was heterogeneous in terms of gene amplification or that amplification was acquired later on as a transition from MYCN gain. We suggest that near-di-/tetraploid 4S tumors with MYCN gain and/or deletion 1p could be progressing 4S tumors.

Entities:  

Mesh:

Year:  2003        PMID: 12645655     DOI: 10.1016/s0165-4608(02)00677-5

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  13 in total

1.  TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.

Authors:  Yania Yáñez; David Hervás; Elena Grau; Silvestre Oltra; Gema Pérez; Sarai Palanca; Mar Bermúdez; Catalina Márquez; Adela Cañete; Victoria Castel
Journal:  J Cancer Res Clin Oncol       Date:  2015-10-24       Impact factor: 4.553

Review 2.  [Neuroblastoma].

Authors:  Victoria Castel; Adela Cañete; Rosa Noguera; Samuel Navarro; Silvestre Oltra
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

3.  Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.

Authors:  Yania Yáñez; Elena Grau; Silvestre Oltra; Adela Cañete; Francisco Martínez; Carmen Orellana; Rosa Noguera; Sarai Palanca; Victoria Castel
Journal:  J Cancer Res Clin Oncol       Date:  2011-06-25       Impact factor: 4.553

4.  2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.

Authors:  Marta Jeison; Shifra Ash; Gili Halevy-Berko; Jacques Mardoukh; Drorit Luria; Smadar Avigad; Galina Feinberg-Gorenshtein; Yacov Goshen; Gabriel Hertzel; Joseph Kapelushnik; Ayelet Ben Barak; Dina Attias; Ran Steinberg; Jerry Stein; Batia Stark; Isaac Yaniv
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

5.  MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors.

Authors:  Elena Grau; Silvestre Oltra; Francisco Martínez; Carmen Orellana; Adela Cañete; Jose María Fernández; Miguel Hernández-Martí; Victoria Castel
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-27       Impact factor: 4.553

6.  Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.

Authors:  Eva Villamón; Marta Piqueras; Carlos Mackintosh; Javier Alonso; Enrique de Alava; Samuel Navarro; Rosa Noguera
Journal:  Virchows Arch       Date:  2008-06-24       Impact factor: 4.064

7.  The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.

Authors:  Dominik Bogen; Clemens Brunner; Diana Walder; Andrea Ziegler; Reza Abbasi; Ruth L Ladenstein; Rosa Noguera; Tommy Martinsson; Gabriele Amann; Freimut H Schilling; Marek Ussowicz; Martin Benesch; Peter F Ambros; Inge M Ambros
Journal:  Int J Cancer       Date:  2016-03-22       Impact factor: 7.396

8.  Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.

Authors:  Eva Villamón; Ana P Berbegall; Marta Piqueras; Irene Tadeo; Victoria Castel; Anna Djos; Tommy Martinsson; Samuel Navarro; Rosa Noguera
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

Review 9.  Molecular biology of neuroblastoma.

Authors:  V Castel; E Grau; R Noguera; F Martínez
Journal:  Clin Transl Oncol       Date:  2007-08       Impact factor: 3.340

10.  Two independent epigenetic biomarkers predict survival in neuroblastoma.

Authors:  Yania Yáñez; Elena Grau; Virginia C Rodríguez-Cortez; David Hervás; Enrique Vidal; Rosa Noguera; Miguel Hernández; Vanessa Segura; Adela Cañete; Ana Conesa; Jaime Font de Mora; Victoria Castel
Journal:  Clin Epigenetics       Date:  2015-02-27       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.